Slide 1: Q2 2025 Earnings and Business Update
a Uitic Q2/2025sEarnings and Business Update
Slide 2: Forward-looking statements
This presentation has been prepared by Compass Therapeutics, Inc . ("we," "us," "our," or the “Company”) . Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the informat
Slide 3: Thomas Schuetz, MD, PhD, CEO and Co-founder
Thomas Schuetz, MD, PhD CEO and Co - founder
Slide 4: Q2 2025 CMPX Program Updates: Executive Summary
Q2 2025 CMPX Program Updates: Executive Summary 4 CTX - 10726 (PD - 1 x VEGF - A) Superior PD - 1 inhibition and tumor control vs ivonescimab in mouse models IND on track for Q4 with commercial scale manufacturing yields CTX - 8371 (PD - 1 x PD - L1) 100% and >90% reductions in target tumor burden i
Slide 5: COMPANION-002: Phase 2/3 U.S. BTC Study
Paclitaxel 80 mg/m 2 Days 1, 8 and 15 of every 28 - day cycle Tovecimig 10mg/kg Days 1 and 15 Paclitaxel 80 mg/m 2 Days 1, 8 and 15 of every 28 - day cycle COMPANION - 002: Phase 2/3 U.S. BTC Study Registrational - intent s tudy in patients who have received one prior line of therapy 5 Crossover per
Slide 6: COMPANION-002 Status as of August 2025
Secondary Endpoints: 80% OS events triggers analyses of overall survival (OS) and progression free survival (PFS) Fewer deaths in the study at this time than projected 80% OS event threshold has not yet been met Analysis of PFS and OS projected to occur in Q1 2026 COMPANION - 002 Status as of August
Slide 7: CTX-8371 x PD-L1 bispecific antibody
CTX - 8371 PD - 1 x PD - L1 bispecific antibody
Slide 8: CTX-8371: Differentiated MoA Leads to Enhanced T-Cell Activation
Bridges T - Cells with APC/Tumor Cells PD - L1 PD - L1 CD28 PD - 1 T - cell CD80 APC or Tumor cell PD - 1 blockers release brake but don’t directly promote T - cell activation _ _ _ _ PD - L1 CD28 PD - 1 CD80 PD - L1 Bridging of PD - 1 expressing T - cells with PD - L1 expressing APCs or tumor cells
Slide 9: CTX-8371: Development Status
Trial Status First patient was dosed in April 2024 No DLTs (12 patients) Enrolling 5 th dose level Initiating cohort expansion (NSCLC & TNBC) Phase 1 Study Design Multiple ascending dose, “3+3” dose - escalation study 5 doses (mg/kg): 0.1 0.3 1.0 3.0 10.0 Post PD - 1 or PD - L1 patient population: M
Slide 10: CTX-8371: Patient with NSCLC
45 mm 18 mm 0 mm CTX - 8371: Patient with NSCLC Target Lesion #1 imaging 10 Non - Small Cell Lung Cancer (n=5) Complete resolution of target tumor lesions in one patient after initial pseudo - progression 4 th line with 59 mm total target lesion burden @ baseline Stable disease in two patients (7+ a
Slide 11: CTX-8371: Patient with TNBC
Week 8 Baseline CTX - 8371: Patient with TNBC Target Lesions #2 and #3 Imaging 11 20 mm 0 mm 52 mm 0 mm >90% reduction in target tumor lesions (4 th line) 87 mm total @ baseline (3 target lesions) to 7 mm at week 12 Non - target lesions also decreased in size Triple - Negative Breast Cancer (n=3) Ri
Slide 12: CTX-10726 x VEGF-A bispecific antibody
CTX - 10726 PD - 1 x VEGF - A bispecific antibody
Slide 13: CTX-10726: Development Pathway
13 CTX - 10726 : PD - 1 x VEGF - A Bispecific CTX - 10726: Development Pathway CTX - 10726 : Drug Discovery and Engineering Fully human, glycosylated IgG1 with silenced Fc - γ receptor binding Anti - VEGF Clinically proven mechanism (bevacizumab) Anti - PD - 1 Proprietary anti - PD - 1 scFv with hig
Slide 14: CTX-10726: Superior Anti-PD-1 Activity Compared to Ivonescimab
14 Data compares anti - PD - 1 arms of ivonescimab and CTX - 10726 No human VEGF - A in this experiment CTX - 10726: Superior Anti - PD - 1 Activity Compared to Ivonescimab Transgenic Mouse Model (MC38) (express human PD - 1/PD - L1) CTX - 10726 Isotype Control Ivonescimab CTX - 10726
Slide 15: CTX-10726: Anti-PD-1 Activity Comparable to Pembrolizumab
15 CTX - 10726: Anti - PD - 1 Activity Comparable to Pembrolizumab Transgenic Mouse Model (MC38) (express human PD - 1/PD - L1) CTX - 10726 Data compares anti - PD - 1 arms of pembrolizumab and CTX - 10726 No human VEGF - A in this experiment Isotype Control Pembrolizumab CTX - 10726
Slide 16: CTX-10726: Superior Anti-Tumor Effect in Preclinical Studies
16 CTX - 10726 0 5 10 15 20 25 0 100 200 300 400 Day A v e r a g e T u m o r V o l u m e ( m m 3 ) PBS PBMCs + Isotype Control PBMCs + CTX-10726 PBMCs + Bevacizumab PBMCs + Ivonescimab Human NSCLC (HCC822) Xenografts Treated with human PBMCs and indicated antibodies Testing both PD - 1 and VEGF - A
Slide 17: Key Anticipated Milestones
Key Anticipated Milestones 2025 H2 H1 17 2026 H2 H1 Tovecimig BTC 17.1% ORR (p=0.031) Ph 2/3 Data (2L) Q1 2026 Ph 2/3 Data (2L) PFS / OS Init. Ph 2 IST (1L) Q4 2026 Ph 2 Data (NCAM) CTX-8371 H1 2025 Ph 1 Dose Escalation H2 2025 Ph 1 Dose Esc. Data Q4 26 / Q1 27 Ph 1 Exp. Cohort Data H2 2026 BLA Fili
Slide 18: Compass Therapeutics
Website: compasstherapeutics.com Nasdaq: CMPX Compass Therapeutics